Ocular FIP treatment gains clarity as antiviral evidence grows

Ocular FIP treatment is getting a clearer clinical picture as newer data suggest antiviral therapy can do more than improve survival alone: it can also resolve ocular signs in many cats, sometimes rapidly, and may reduce the need for aggressive local intervention when started promptly. The latest evidence highlighted in VetGirl’s “Ocular FIP – A New Vision For Treatment” podcast aligns with a 2024 observational case series reporting outcomes in cats with ocular involvement treated with remdesivir alone or with GS-441524. VetGirl also underscored a useful clinical point for general practice: ocular disease is seen much more often in the dry form of FIP than the wet form, and in some cats uveitis may be the dominant presenting feature. In that series, most cats with ocular FIP were treated at 15 to 20 mg/kg once daily, and one cat with panuveitis had complete resolution of ocular disease on antiviral therapy alone during the treatment course. The discussion also lands in a changed U.S. practice environment: since the FDA’s May 10, 2024 enforcement announcement, veterinarians have had a defined pathway to prescribe compounded GS-441524 for individual feline patients with FIP under GFI #256 conditions, while oral compounded GS-441524 became commercially available in the U.S. through Stokes Pharmacy and Bova beginning June 1, 2024. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, ocular FIP is no longer just a grave diagnostic clue tied to limited options. It’s increasingly a treatable manifestation of systemic disease, though dosing, duration, and monitoring still matter, especially in cats with ocular or neurologic involvement. A recent systematic review covering studies from 2018 to 2024 found substantial evidence supporting GS-441524 across FIP presentations, including cases with ocular and neurologic signs, while a 2025 Scientific Reports analysis concluded that GS-441524, at sufficient dosage, was a viable option for surviving cats with ocular and/or neurologic FIP. VetGirl’s related coverage on dosing and duration also emphasized why these cases still warrant caution: cats often improve clinically within about a week, but that early response does not necessarily mean viral clearance, particularly in harder-to-penetrate sites like the eyes and central nervous system. The practical shift is that clinicians now have more legitimate prescribing options than they did before June 2024, but they still need to counsel pet parents carefully that compounded GS-441524 remains unapproved by FDA, even if the agency has said it does not intend to enforce approval requirements in certain patient-specific circumstances. (pmc.ncbi.nlm.nih.gov)

What to watch: Expect more discussion around optimal dosing for ocular and neurologic cases, relapse prevention, and whether oral versus injectable protocols produce meaningfully different ophthalmic outcomes as more real-world U.S. treatment data emerge. Also watch for greater use of objective treatment-stop criteria, including acute phase proteins such as serum amyloid A and alpha-1 acid glycoprotein plus albumin:globulin ratio trends, rather than relying on early clinical improvement alone. (pmc.ncbi.nlm.nih.gov)